Skip to the page

Data / Drug companies / Amneal Pharmaceuticals of New York LLC

Amneal Pharmaceuticals of New York LLC: 109 products in the FDA NDC directory, labeler code 53746

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Amneal Pharmaceuticals of New York LLC (labeler code 53746) lists 109 products in the FDA National Drug Code Directory, covering 42 finished drugs by generic name. By type: 100 prescription drugs, 9 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on May 22, 2025.

The request: Watch Amneal Pharmaceuticals of New York LLC (FDA labeler code 53746): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
53746
Products in commercial distribution
109
Packages
267
Finished drugs by generic name
42
Prescription products
100
Over the counter products
9
Controlled substance products
Schedule II 8, Schedule III 2, Schedule IV 3, Schedule V 4
Flagged as original packager
106 of 106 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
November 27, 2007
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)10798.2%
Other unapproved drugs21.8%

Products by type

TypeProductsShare
Prescription drugs10091.7%
Over the counter drugs98.3%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet7770.6%
Tablet, film coated1412.8%
Capsule87.3%
Tablet, coated54.6%
Powder, for solution10.9%
Capsule, extended release10.9%
Capsule, delayed release10.9%
Insert10.9%
Suspension/ drops10.9%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Budesonide53746-778Capsule, delayed releaseGeneric drugs (ANDA)May 22, 2025
Lurasidone Hydrochloride53746-882Tablet, coatedGeneric drugs (ANDA)July 5, 2024
Lurasidone Hydrochloride53746-881Tablet, coatedGeneric drugs (ANDA)July 5, 2024
Lurasidone Hydrochloride53746-880Tablet, coatedGeneric drugs (ANDA)July 5, 2024
Lurasidone Hydrochloride53746-879Tablet, coatedGeneric drugs (ANDA)July 5, 2024
Lurasidone Hydrochloride53746-082Tablet, coatedGeneric drugs (ANDA)July 5, 2024
Clindamycin Palmitate Hydrochloride (Pediatric)53746-468Powder, for solutionGeneric drugs (ANDA)April 1, 2024
Ciprofloxacin and Dexamethasone53746-831Suspension/ dropsGeneric drugs (ANDA)March 26, 2024
Temazepam53746-557CapsuleGeneric drugs (ANDA)February 19, 2024
Temazepam53746-556CapsuleGeneric drugs (ANDA)February 19, 2024
Alosetron Hydrochloride53746-249Tablet, film coatedGeneric drugs (ANDA)September 6, 2023
Alosetron Hydrochloride53746-248Tablet, film coatedGeneric drugs (ANDA)September 6, 2023
Valsartan and Hydrochlorothiazide53746-849Tablet, film coatedGeneric drugs (ANDA)August 14, 2023
Valsartan and Hydrochlorothiazide53746-848Tablet, film coatedGeneric drugs (ANDA)August 14, 2023
Valsartan and Hydrochlorothiazide53746-847Tablet, film coatedGeneric drugs (ANDA)August 14, 2023
Valsartan and Hydrochlorothiazide53746-846Tablet, film coatedGeneric drugs (ANDA)August 14, 2023
Valsartan and Hydrochlorothiazide53746-845Tablet, film coatedGeneric drugs (ANDA)August 14, 2023
Valsartan53746-839TabletGeneric drugs (ANDA)August 1, 2023
Valsartan53746-838TabletGeneric drugs (ANDA)August 1, 2023
Valsartan53746-837TabletGeneric drugs (ANDA)August 1, 2023
Lacosamide53746-926TabletGeneric drugs (ANDA)May 17, 2023
Lacosamide53746-925TabletGeneric drugs (ANDA)May 17, 2023
Lacosamide53746-924TabletGeneric drugs (ANDA)May 17, 2023
Lacosamide53746-923TabletGeneric drugs (ANDA)May 17, 2023
Valsartan53746-840TabletGeneric drugs (ANDA)October 10, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.